Every 424B that Dermata Therapeutics Inc (DRMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DRMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRMA filings page.
Dermata Therapeutics, Inc. registers an aggregate $100,000,000 shelf to offer common stock, preferred stock, warrants, debt securities, subscription rights and units.
The prospectus states the aggregate public offering price will not exceed $100,000,000, that offerings will be made from time to time on market-driven terms, and that the company’s common stock and certain warrants trade on Nasdaq under the symbols DRMA and DRMAW. The prospectus discloses a public float of $3,955,179.64 based on 3,189,661 public shares at a closing price of $1.24 per share and reports 4,022,143 shares of common stock outstanding as of May 21, 2026.
Dermata Therapeutics, Inc. filed a resale prospectus covering up to 6,207,730 shares of common stock for selling stockholders. This includes 1,484,312 shares already issued, 537,750 pre-funded warrant shares, 2,022,062 Series C warrant shares, 2,022,062 Series D warrant shares, and 141,544 placement agent warrant shares.
The company will not receive proceeds from share resales but may receive cash if warrants are exercised, at $2.04 per share for the Series C and Series D Warrants and $2.55 for the Placement Agent Warrants. Dermata is pivoting from prescription drugs to over-the-counter dermatology products built on its Spongilla technology, with a planned mid‑2026 launch of a once‑weekly topical acne kit using salicylic acid. A 1‑for‑10 reverse stock split became effective on August 1, 2025, and all share figures reflect this adjustment.
DRMA is updating its at-the-market stock offering program to allow additional sales of its common stock with an aggregate offering price of up to $705,000 through H.C. Wainwright & Co. under an existing Form S-3 shelf. This amount is in addition to approximately $3,454,390 of common stock previously sold under earlier prospectus supplements. The filing reflects the limits of General Instruction I.B.6 of Form S-3, which restricts primary offerings to no more than one-third of public float in any 12-month period while public float is below $75.0 million. The company reports a public float of about $7,493,999, based on 2,386,624 shares held by non-affiliates as of January 23, 2026, at a reference price of $3.14 per share, and notes that about $1,792,248 of securities have been sold under these limits in the last twelve months.
Dermata Therapeutics (DRMA) filed a prospectus supplement for its at-the-market program, permitting sales of up to $1,792,315 of common stock through H.C. Wainwright & Co. under its effective S-3, subject to General Instruction I.B.6 limitations.
This cap reflects a public float of approximately $5,376,945, calculated on 910,575 non‑affiliate shares at $5.905 as of September 16, 2025. The amount does not include approximately $1,662,142 previously sold under earlier supplements. Any additional sales capacity will be addressed in a subsequent supplement.
DRMA’s common stock trades on Nasdaq under “DRMA”; the last reported sale price was $2.95 on November 6, 2025. The company is an emerging growth company and smaller reporting company.